

PRISMA 2020 Checklist

Section and Topic	ltem #	Checklist item	Location where item is reported						
TITLE	-								
Title	1	Identify the report as a systematic review.	Yes Page 1 Line 2						
ABSTRACT	-								
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page 1 Line 4						
INTRODUCTION	-								
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Yes Page 3 Line 3						
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 3 Line 26 and Supplement-2 with PICO statements						
METHODS	-								
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Page 4 Line 7						
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify he date when each source was last searched or consulted.							
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.							
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.							
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page 4 Line 5 and Line 26						
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Page 4 Line 31-39						
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page 4 Line 31						
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Page 4 Line 42						
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Page 5 Line 1- 2						
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Page 4 Line 15						
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Page 4 Line 31-39						
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Page 5 Line 35						



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported							
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Page 4 Line 47							
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Page 5 Line-1							
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Page 5 line 2							
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Page 4 Line 41							
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	GRADE-Page 5 Line-3							
RESULTS										
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page 5 Line 7							
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Page 5 line 12							
Study characteristics	17	Cite each included study and present its characteristics.	Page 5 Line 15							
Risk of bias in studies	18	esent assessments of risk of bias for each included study.								
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.								
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.								
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.								
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Page 5 Line 15							
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Page 7 Line 40							
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Supplementary material-3							
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Supplement-6							
DISCUSSION	•	·								
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page 8 line 27- 39							
	23b	Discuss any limitations of the evidence included in the review.	Page 9 Line 1							
	23c	Discuss any limitations of the review processes used.	Page 10 line 9							
	23d	Discuss implications of the results for practice, policy, and future research.	Page 10 Line							



Section and Topic	ltem #	Checklist item	Location where item is reported
			20
OTHER INFORMA	TION		
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page 3 Line 41
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Page 3 Line 40
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	Page 3 Line 41
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 11 Line 4
Competing interests	26	Declare any competing interests of review authors.	Page 11 Line 6
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Supplementary material 1-6

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <u>http://www.prisma-statement.org/</u>

Supplementary material 2

Review Question

In adult patients with an acute ischemic stroke due to a large vessel occlusion who undergo thrombectomy does an intensive blood pressure control (Target SBP cutoff as defined by the respective study or upper limit of target SBP cut-off of 140mmHg) as compared to a less intensive blood pressure control up to 24 hours after the procedure lead to a good functional outcome?

Population	All adult (>18years) patients of acute ischemic stroke due to a large vessel
	occlusion undergoing thrombectomy.
Intervention	Intensive Blood Pressure Control (Target SBP cutoff as defined in the
	respective study definition) up to 24 hours after the procedure.
Control	Less Intensive Blood Pressure Control (Target SBP cutoff as defined by
	the respective study definition) up to 24 hours after the procedure.
Primary	Proportion of patients achieving functional independence at 90 days
Efficacy	defined as mRS of 0-2.
Outcome	

Table1-PICO Statements

SBP-Systolic Blood Pressure; mRS-modified Rankin Scale

Safety outcomes assessed-

1.Death at 90days

2.Requirement of decompressive surgery

3.Symptomatic ICH as per respective study definition.

Supplement-3

Risk of Bias Table-1-New Castle Ottawa Scale

			Selec	tion			Comp Outcome						
Sl No	Author	Year	Repr	Selea	Ascer	Demoi	Comp	Assess	Was fol	Adeq	Total Stars	Total Stars co	Impression
1	Goyal et al	2017	*	*	*	*	**	*	*	*	****	9	Good
2	Eva A. Mistr	2019	*	*	*	*	*	*	*	*	*****	8	Good
3	Anadani et al	2019	*	*	*	*	*	0	*	*	****	7	Good
4	Chang et al	2019	*	*	*	*	**	*	*	*	*****	9	Good
5	Cernik D et a	2019	*	*	*	*	**	0	*	*	****	8	Good
6	Anadani et al	2020	*	*	*	*	**	0	*	*	*****	8	Good
7	Han et al	2021	*	*	*	*	**	*	*	*	****	9	Good
8	P. Upadhyay	2023	*	*	*	*	**	0	*	*	*****	8	Good
												8.25	
												8	

Table-2-ROB2 tool for the studies included

As Stut Ret Exp Co Ou Ret Ain Eff We Uomain 1. R Sol	me nique ID sessor udy ID ference perimental omparator utcome sults	2024/03/02 20.36 Dr.Baikunha Yang 2022 Yang 2022 Intensive Control	1 2 Dr.Baikuntha Mazighi 2021 Mazighi 2021	3 Dr.Baikuntha Nam 2023 Nam 2023	4 Dr.Baikuntha Mistry 2023
As Stut Ret Exp Co Ou Ret Ain Eff We Uomain 1. R Sol	ssessor udy ID eference cperimental mparator utcome	Yang 2022 Yang 2022 Intensive Control	Dr.Baikuntha Mazighi 2021	Dr.Baikuntha Nam 2023	Dr.Baikuntha
As Stut Ret Exp Co Ou Ret Ain Eff We Uomain 1. R Sol	ssessor udy ID eference cperimental mparator utcome	Yang 2022 Yang 2022 Intensive Control	Mazighi 2021	Dr.Baikuntha Nam 2023	Dr.Baikuntha
Stu Rei Exy Co Ou Rei Airi Eff We Domain 1. R Sou No	udy ID eference xperimental omparator utcome	Yang 2022 Yang 2022 Intensive Control	Mazighi 2021	Nam 2023	
Rei Exy Co Ou Rei Aii Eff We Domain 1. R So No	eference xperimental omparator utcome	Yang 2022 Intensive Control			Wilsu y 2025
Exy Co Ou Re: Eff We Domain 1. R Sor No	xperimental omparator utcome	Intensive Control	Wazigini 2021		Mistry 2023
Co Ou Re: Air Eff We Domain 1. R Sou No	omparator utcome		T		
Ou Res Air Eff Domain 1. R Son No	utcome		Intensive Control	Intensive Control	Intensive Control
Re: Air Eff We Domain 1. R Sou No		Conventional	Conventional	Conventional	Conventional
Air Eff We Domain 1. R Sou	esults	mRS 0-2	mRS 0-2	mRS 0-2	mRS 0-2
Eff We Domain 1. R Sou No					
We Domain 1. R Sou No	im	assignment to intervention (the 'intent	o assignment to intervention (the 'intention	assignment to intervention (the 'inten	assignment to intervention (the 'intention-t
We Domain 1. R Sou No	fect of adhering to intervention?	NA	NA	NA	NA
Domain 1. R Son	eight				
No		Iournal article(s): Trial protocol: Stat	st Journal article(s): Trial protocol: Statisti	Iournal article(s): Trial protocol: Sta	Journal article(s); Trial protocol; Statistica
		I Y	Y	Y	Y
		2 Y	Y	Y	Ŷ
		2 1	1	1	1
	ote for 1.1&1.2		N.		× 7
		3 N	N	N	N
	ote for 1.3				
	0 Algorithm result				
1.0	0 Assessor's Judgement	Low	Low	Low	Low
Domain 2. D 1.0	0 General note				
1.0	0 Optional Question				
	0 Note for optional question				
1.0		I Y	Y	Y	Y
		2 Y	Y	Y	Y
		- 1	1	1	1
No	ote for 2.1&2.2	N DX/	X/	¥7	N/
		3 PY	Y	Y	Y
No	ote for 2.3				
	2	4 PY	Y	Y	Y
No	ote for 2.4				
		5 PY	PY	PY	PY
No	ote for 2.5				
110		5 Y	N	N	N
N		5 1	IN	IN	1N
	ote for 2.6				
Domain 3. M		7 NA			
No	ote for 2.7				
2.0	0 Algorithm result				
2.0	0 Assessor's Judgement	Some concerns	High	High	High
2.0	0 General Notes				
	0 Optional Question				
	0 Note for optional question				
2.0		1 XZ	v	X/	V
		I Y	Y	Y	Y
	ote for 3.1				
Domain 4. M		2 NA			
No	ote for 3.2				
		3 NA			
No	ote for 3.3&3.4				
	3.4	1 NA			
3.0	0 Algorithm result				
	0 Assessor's judgement	Low	Low	Low	Low
	0 Gerenal notes				
	0 Optional Question				
3.0	0 Note for optional question	1 N	N	N	NT
		I N	N	N	N
Domain 5. S(No					
		2 N	N	N	N
No	ote for 4.2				
	4.:	3 N	N	N	N
No	ote for 4.3				
		4 NA			
No	ote for 4.4&4.5		1		
INO		5 NA			
		5 NA			
1.0	0 Algorithm result	-		*	*
	0 Assessor's Judgement	Low	Low	Low	Low
	0 General note				
	0 Optional Question				
4.0	0 Note for optional question				
		I Y	Y	Y	Y
No	ote for 5.1				
		2 N	N	N	N
NLa	ote for 5.2				
INO		2 21	N	N	NT.
		3 N	N	N	N
	ote for 5.3				
	0 Algorithm result				
	0 Assessor's Judgement	Low	Low	Low	Low
5.0	0 General note				
5.0	0 Optional Question				
	0 Note for optional question				
15.0	lgorithm's overall Judgement				
	ssessor's overall Judgement	Some concerns	High risk	High risk	High risk

Supplement-4

Supplemental Figure-1-Death at 90 days using data from studies using different SBP targets to define intensive control

Combined analysis(n=7) of studies with SBP cut-off of 140mmHg to define intensive control

•	Intens	ive	Convent	ional		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	r M-H, Random, 95% CI
Goyal et al 2017	0	10	30	130	0.6%	0.20 [0.01, 2.98]	2017	·
Cernik D et al 2019	88	376	101	314	27.0%	0.73 [0.57, 0.93]	2019) 🗕
Chang et al 2019	5	48	6	42	0.0%	0.73 [0.24, 2.22]	2019)
Eva A. Mistry et al 2019	20	179	59	267	0.0%	0.51 [0.32, 0.81]	2019)
Anadani et al 2019	150	942	67	259	26.2%	0.62 [0.48, 0.79]	2019)
Anadani et al 2020	84	540	91	479	25.0%	0.82 [0.63, 1.07]	2020) –=-
Han et al 2021	21	96	12	83	8.9%	1.51 [0.79, 2.89]	2021	· +•
Mazighi et al 2021	29	152	21	153	0.0%	1.39 [0.83, 2.33]	2021	
Yang et al 2022	66	406	61	408	0.0%	1.09 [0.79, 1.50]	2022	2
Mistry et al 2023	7	37	20	76	6.8%	0.72 [0.33, 1.55]	2023	
Nam et al 2023	12	155	8	147	5.5%	1.42 [0.60, 3.38]	2023	·
P. Upadhyaya et al 2023	5	44	9	59	0.0%	0.74 [0.27, 2.07]	2023	
Total (95% CI)		2156		1488	100.0%	0.79 [0.63, 0.98]		•
Total events	362		329					
Heterogeneity: Tau ² = 0.0	3; Chi ² =	10.42,	df = 6 (P	= 0.11); I ² = 42	%		
Test for overall effect: Z =	2.15 (P =	= 0.03)						'0.01 0.1 1 10 100' Favours intensive Favours conventional

Observational studies(n=5) with SBP cut-off of 140mmHg to define intensive control

	Intensive Arm			al Arm		Risk Ratio		Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M–H, Random, 95% CI				
Goyal et al 2017	0	10	30	130	0.7%	0.20 [0.01, 2.98]	2017					
Eva A. Mistry et al 2019	20	179	59	267	0.0%	0.51 [0.32, 0.81]	2019					
Anadani et al 2019	150	942	67	259	29.8%	0.62 [0.48, 0.79]	2019					
Cernik D et al 2019	88	376	101	314	30.6%	0.73 [0.57, 0.93]	2019					
Chang et al 2019	5	48	6	42	0.0%	0.73 [0.24, 2.22]	2019					
Anadani et al 2020	84	540	91	479	28.5%	0.82 [0.63, 1.07]	2020					
Han et al 2021	21	96	12	83	10.4%	1.51 [0.79, 2.89]	2021	+				
P. Upadhyaya et al 2023	5	44	9	59	0.0%	0.74 [0.27, 2.07]	2023					
Total (95% CI)		1964		1265	100.0%	0.76 [0.60, 0.97]		•				
Total events	343		301									
Heterogeneity: Tau ² = 0.02	3; Chi ² = 8	.23, df	= 4 (P = 0.08)); $I^2 = 51$	1%			0.01 0.1 1 10	100			
Test for overall effect: Z =	2.21 (P =	0.03)						Favours Intensive Control Favours Conventional	100			
DCT-($PCTe(n=2)$ with SRP out_off of 140mmHg to define intensive control Favours intensive Control Favours Conventional											


RCTs(n=2) with SBP cut-off of 140mmHg to define intensive control

	Intensive Co	ontrol	Conventional C	ontrol		Risk Ratio		Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	r M-H, Random, 95% CI			
Mazighi et al 2021	29	152	21	153	0.0%	1.39 [0.83, 2.33]	2021	L			
Yang et al 2022	66	406	61	408	0.0%	1.09 [0.79, 1.50]	2022	2			
Nam et al 2023	12	155	8	147	45.5%	1.42 [0.60, 3.38]	2023	3			
Mistry et al 2023	7	37	20	76	54.5%	0.72 [0.33, 1.55]	2023	3			
Total (95% CI)		192		223	100.0%	0.98 [0.50, 1.91]		+			
Total events	19		28								
Heterogeneity: Tau ² =	0.06; Chi ² =	1.34, df	f = 1 (P = 0.25); f	² = 26%				0.01 0.1 1 10 100			
Test for overall effect:	Z = 0.06 (P =	0.95)						Favours Intensive Favours Conventional			

Combined Analysis of studies(n=3) using a SBP cut-off of 130mmHg (Death@90d) for intensive control

control								
	Intensive Conventional					Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Goyal et al 2017	0	10	30	130	0.0%	0.20 [0.01, 2.98]	2017	
Cernik D et al 2019	88	376	101	314	0.0%	0.73 [0.57, 0.93]	2019	
Chang et al 2019	5	48	6	42	14.6%	0.73 [0.24, 2.22]	2019	
Eva A. Mistry et al 2019	20	179	59	267	0.0%	0.51 [0.32, 0.81]	2019	
Anadani et al 2019	150	942	67	259	0.0%	0.62 [0.48, 0.79]	2019	
Anadani et al 2020	84	540	91	479	0.0%	0.82 [0.63, 1.07]	2020	
Han et al 2021	21	96	12	83	0.0%	1.51 [0.79, 2.89]	2021	
Mazighi et al 2021	29	152	21	153	68.1%	1.39 [0.83, 2.33]	2021	+=-
Yang et al 2022	66	406	61	408	0.0%	1.09 [0.79, 1.50]	2022	
Mistry et al 2023	7	37	20	76	0.0%	0.72 [0.33, 1.55]	2023	
Nam et al 2023	12	155	8	147	0.0%	1.42 [0.60, 3.38]	2023	
P. Upadhyaya et al 2023	5	44	9	59	17.3%	0.74 [0.27, 2.07]	2023	
Total (95% CI)		244		254	100.0%	1.14 [0.74, 1.74]		+
Total events	39		36					-
Heterogeneity: Tau ² = 0.0	0; Chi ² =	1.86, 0	df = 2 (P =	= 0.39);	$I^2 = 0\%$			0.01 0.1 1 10 100
Test for overall effect: Z =	0.59 (P =	= 0.56)						0.01 0.1 1 10 100 Favours intensive Favours conventional
								ravours intensive ravours conventional

Supplemental Figure-2 Symptomatic intracranial haemorrhage(sICH) using data from studies using different SBP targets to define intensive control



P. Upadhyaya et al 2023

Test for overall effect: Z = 0.03 (P = 0.97)

Mistry et al 2023

Total (95% CI)

Total events

1

2

18

Heterogeneity: Tau² = 0.54; Chi² = 1.80, df = 1 (P = 0.18); I² = 44%

44

37

198

4

3

15

59

72

216 100.0%

27.9%

0.0%

0.34 [0.04, 2.90] 2023

1.30 [0.23, 7.43] 2023

0.01

0.1

10

Favours Intensive Favours Conventional

100

1.02 [0.26, 4.02]

Supplemental Figure-3 Decompressive surgery using data from studies using different SBP targets to define intensive control

Combined Analysis(n=2) for studies using a SBP cut-off of 140mmHg for intensive control

	Intensive Co			ional		Risk Ratio		Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI				
Anadani et al 2019	31	942	19	259	58.9%	0.45 [0.26, 0.78]	2019					
Anadani et al 2020	11	540	34	479	41.1%	0.29 [0.15, 0.56]	2020					
Mazighi et al 2021	1	158	0	162	0.0%	3.08 [0.13, 74.93]	2021					
P. Upadhyaya et al 2023	1	44	1	59	0.0%	1.34 [0.09, 20.85]	2023					
Total (95% CI)		1482		738	100.0%	0.37 [0.24, 0.58]		◆				
Total events	42		53									
Heterogeneity: Tau ² = 0.0	0; Chi ² =	1.05, 0	df = 1 (P =	= 0.31);	$I^2 = 4\%$			0.01 0.1 1 10 100				
Test for overall effect: Z =	4.42 (P <	< 0.000	001)					Favours Intensive Favours Conventional				

Combined Analysis(n=2) for studies using a SBP cut-off of 130mmHg for intensive control Intensive Conventional Risk Ratio Risk Ratio

	meens		convent	Tonal		Max Matte		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M–H, Random, 95% CI
Anadani et al 2019	31	942	19	259	0.0%	0.45 [0.26, 0.78]	2019	
Anadani et al 2020	11	540	34	479	0.0%	0.29 [0.15, 0.56]	2020	
Mazighi et al 2021	1	158	0	162	42.5%	3.08 [0.13, 74.93]	2021	
P. Upadhyaya et al 2023	1	44	1	59	57.5%	1.34 [0.09, 20.85]	2023	
Total (95% CI)		202		221	100.0%	1.91 [0.24, 15.29]		
Total events	2		1					
Heterogeneity: Tau ² = 0.00	0; Chi ² =	0.15, 0	df = 1 (P =	= 0.70);	$ ^2 = 0\%$		⊢ 0.0	01 0.1 1 10 100
Test for overall effect: Z =	0.61 (P =	= 0.54)					0.0	Favours Intensive Favours Conventional

Supplement-2-Leave out one study analysis

Studies in **bold** and having a * had a significant change in the primary outcome after leaving them out.

Leave out Goyal et al 2017

•	Intensive Mana	gement	Conventional Manage	ement		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl
Goyal et al 2017	7	10	67	130	0.0%	1.36 [0.88, 2.11]	2017	
Anadani et al 2019	485	942	92	259	10.4%	1.45 [1.22, 1.73]	2019	+
Cernik D et al 2019	202	376	132	314	10.6%	1.28 [1.09, 1.50]	2019	+
Chang et al 2019	32	48	17	42	6.9%	1.65 [1.08, 2.50]	2019	
Eva A. Mistry et al 2019	96	179	90	267	9.8%	1.59 [1.28, 1.98]	2019	-
Anadani et al 2020	283	540	222	479	10.9%	1.13 [1.00, 1.28]	2020	-
Han et al 2021	38	96	27	83	7.2%	1.22 [0.82, 1.81]	2021	+
Mazighi et al 2021	67	152	69	153	9.3%	0.98 [0.76, 1.26]	2021	+
Yang et al 2022	192	404	247	406	10.9%	0.78 [0.69, 0.89]	2022	+
P. Upadhyaya et al 2023	28	44	27	59	7.8%	1.39 [0.97, 1.99]	2023	
Mistry et al 2023	17	37	36	76	6.8%	0.97 [0.64, 1.48]	2023	
Nam et al 2023	61	155	80	147	9.4%	0.72 [0.57, 0.92]	2023	-
Total (95% CI)		2973		2285	100.0%	1.15 [0.96, 1.36]		•
Total events	1501		1039					
Heterogeneity: $Tau^2 = 0.0$	7; Chi ² = 69.63, d	f = 10 (P)	< 0.00001 ; $I^2 = 86\%$					
Test for overall effect: Z =								0.01 0.1 1 10 100 Favours [conventional] Favours [intensive]

Leave out Anadani et al 2019

	Intensive Manag	gement	Conventional Manage	ment		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Goyal et al 2017	7	10	67	130	6.8%	1.36 [0.88, 2.11]	2017	
Anadani et al 2019	485	942	92	259	0.0%	1.45 [1.22, 1.73]	2019	
Cernik D et al 2019	202	376	132	314	11.0%	1.28 [1.09, 1.50]	2019	+
Chang et al 2019	32	48	17	42	7.1%	1.65 [1.08, 2.50]	2019	_ _ _
Eva A. Mistry et al 2019	96	179	90	267	10.2%	1.59 [1.28, 1.98]	2019	-
Anadani et al 2020	283	540	222	479	11.5%	1.13 [1.00, 1.28]	2020	-
Han et al 2021	38	96	27	83	7.4%	1.22 [0.82, 1.81]	2021	
Mazighi et al 2021	67	152	69	153	9.7%	0.98 [0.76, 1.26]	2021	+
Yang et al 2022	192	404	247	406	11.4%	0.78 [0.69, 0.89]	2022	-
P. Upadhyaya et al 2023	28	44	27	59	8.0%	1.39 [0.97, 1.99]	2023	
Mistry et al 2023	17	37	36	76	7.0%	0.97 [0.64, 1.48]	2023	_ _ _
Nam et al 2023	61	155	80	147	9.8%	0.72 [0.57, 0.92]	2023	-
Total (95% CI)		2041		2156	100.0%	1.13 [0.95, 1.34]		•
Total events	1023		1014					·
Heterogeneity: $Tau^2 = 0.0$	06; Chi ² = 59.51, d	f = 10 (P	< 0.00001 ; $I^2 = 83\%$					
Test for overall effect: Z =	1.39 (P = 0.17)							0.01 0.1 i 10 100 Favours [conventional] Favours [intensive]

Leave out Cernik et al 2019

	Intensive Mana	gement	Conventional Manag	jement		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Goyal et al 2017	7	10	67	130	7.0%	1.36 [0.88, 2.11]	2017	
Anadani et al 2019	485	942	92	259	10.7%	1.45 [1.22, 1.73]	2019	+
Cernik D et al 2019	202	376	132	314	0.0%	1.28 [1.09, 1.50]	2019	
Chang et al 2019	32	48	17	42	7.3%	1.65 [1.08, 2.50]	2019	
Eva A. Mistry et al 2019	96	179	90	267	10.1%	1.59 [1.28, 1.98]	2019	-
Anadani et al 2020	283	540	222	479	11.2%	1.13 [1.00, 1.28]	2020	-
Han et al 2021	38	96	27	83	7.6%	1.22 [0.82, 1.81]	2021	
Mazighi et al 2021	67	152	69	153	9.7%	0.98 [0.76, 1.26]	2021	+
Yang et al 2022	192	404	247	406	11.2%	0.78 [0.69, 0.89]	2022	+
P. Upadhyaya et al 2023	28	44	27	59	8.2%	1.39 [0.97, 1.99]	2023	
Mistry et al 2023	17	37	36	76	7.3%	0.97 [0.64, 1.48]	2023	
Nam et al 2023	61	155	80	147	9.8%	0.72 [0.57, 0.92]	2023	
Total (95% CI)		2607		2101	100.0%	1.15 [0.95, 1.38]		◆
Total events	1306		974					
Heterogeneity: $Tau^2 = 0.0$	$7; Chi^2 = 66.62, c$	lf = 10 (P	< 0.00001 ; $I^2 = 85\%$				F	
Test for overall effect: $7 =$	1.46 (P = 0.14)						0.	01 0.1 i 10 100

Heterogeneity: Tau² = 0.07; Chi² = 66.62, df = 10 (P < 0.00001); I² Test for overall effect: Z = 1.46 (P = 0.14)

0.01 0.1 1 10 Favours [conventional] Favours [intensive]

Leave out Chang et al 2019

	Intensive Manag	gement	Conventional Manage	ement		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Goyal et al 2017	7	10	67	130	6.6%	1.36 [0.88, 2.11]	2017	+
Anadani et al 2019	485	942	92	259	10.4%	1.45 [1.22, 1.73]	2019	+
Cernik D et al 2019	202	376	132	314	10.6%	1.28 [1.09, 1.50]	2019	-
Chang et al 2019	32	48	17	42	0.0%	1.65 [1.08, 2.50]	2019	
Eva A. Mistry et al 2019	96	179	90	267	9.9%	1.59 [1.28, 1.98]	2019	-
Anadani et al 2020	283	540	222	479	11.0%	1.13 [1.00, 1.28]	2020	-
Han et al 2021	38	96	27	83	7.2%	1.22 [0.82, 1.81]	2021	+-
Mazighi et al 2021	67	152	69	153	9.4%	0.98 [0.76, 1.26]	2021	+
Yang et al 2022	192	404	247	406	11.0%	0.78 [0.69, 0.89]	2022	+
P. Upadhyaya et al 2023	28	44	27	59	7.7%	1.39 [0.97, 1.99]	2023	
Mistry et al 2023	17	37	36	76	6.8%	0.97 [0.64, 1.48]	2023	
Nam et al 2023	61	155	80	147	9.4%	0.72 [0.57, 0.92]	2023	-
Total (95% CI)		2935		2373	100.0%	1.13 [0.95, 1.34]		•
Total events	1476		1089					
Heterogeneity: $Tau^2 = 0.0$	6; $Chi^2 = 66.82$, d	f = 10 (P)	< 0.00001 ; $I^2 = 85\%$					
Test for overall effect: Z =								0.01 0.1 1 10 100 Favours [conventional] Favours [intensive]

Leave out Mistry et al 2019

	Intensive Mana	gement	Conventional Manage	ement		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M–H, Random, 95% CI
Goyal et al 2017	7	10	67	130	6.6%	1.36 [0.88, 2.11]	2017	
Anadani et al 2019	485	942	92	259	10.9%	1.45 [1.22, 1.73]	2019	+
Cernik D et al 2019	202	376	132	314	11.1%	1.28 [1.09, 1.50]	2019	-
Chang et al 2019	32	48	17	42	6.9%	1.65 [1.08, 2.50]	2019	_ _ _
Eva A. Mistry et al 2019	96	179	90	267	0.0%	1.59 [1.28, 1.98]	2019	
Anadani et al 2020	283	540	222	479	11.5%	1.13 [1.00, 1.28]	2020	+
Han et al 2021	38	96	27	83	7.3%	1.22 [0.82, 1.81]	2021	
Mazighi et al 2021	67	152	69	153	9.7%	0.98 [0.76, 1.26]	2021	+
Yang et al 2022	192	404	247	406	11.5%	0.78 [0.69, 0.89]	2022	+
P. Upadhyaya et al 2023	28	44	27	59	7.9%	1.39 [0.97, 1.99]	2023	
Mistry et al 2023	17	37	36	76	6.9%	0.97 [0.64, 1.48]	2023	_
Nam et al 2023	61	155	80	147	9.7%	0.72 [0.57, 0.92]	2023	-
Total (95% CI)		2804		2148	100.0%	1.12 [0.95, 1.32]		•
Total events	1412		1016					
Heterogeneity: $Tau^2 = 0.0$	6; $Chi^2 = 58.39$, c	lf = 10 (P	< 0.00001 ; $I^2 = 83\%$					
Test for overall effect: Z =	1.33 (P = 0.18)							0.01 0.1 1 10 100 Favours [conventional] Favours [intensive]
								ravours (conventional) Favours (intensive)

Test for overall effect: Z = 1.33 (P = 0.18)

Leave out Anadani et al 2020

	Intensive Manag	gement	Conventional Manage	ement		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M–H, Random, 95% CI
Goyal et al 2017	7	10	67	130	7.3%	1.36 [0.88, 2.11]	2017	+ - -
Anadani et al 2019	485	942	92	259	10.5%	1.45 [1.22, 1.73]	2019	+
Cernik D et al 2019	202	376	132	314	10.7%	1.28 [1.09, 1.50]	2019	+
Chang et al 2019	32	48	17	42	7.5%	1.65 [1.08, 2.50]	2019	
Eva A. Mistry et al 2019	96	179	90	267	10.1%	1.59 [1.28, 1.98]	2019	-
Anadani et al 2020	283	540	222	479	0.0%	1.13 [1.00, 1.28]	2020	
Han et al 2021	38	96	27	83	7.8%	1.22 [0.82, 1.81]	2021	
Mazighi et al 2021	67	152	69	153	9.7%	0.98 [0.76, 1.26]	2021	+
Yang et al 2022	192	404	247	406	11.0%	0.78 [0.69, 0.89]	2022	+
P. Upadhyaya et al 2023	28	44	27	59	8.3%	1.39 [0.97, 1.99]	2023	
Mistry et al 2023	17	37	36	76	7.5%	0.97 [0.64, 1.48]	2023	_ _ _
Nam et al 2023	61	155	80	147	9.7%	0.72 [0.57, 0.92]	2023	-
Total (95% CI)		2443		1936	100.0%	1.16 [0.96, 1.41]		•
Total events	1225		884					
Heterogeneity: $Tau^2 = 0.0$	9; Chi ² = 70.32, d	f = 10 (P)	< 0.00001 ; $I^2 = 86\%$					
Test for overall effect: Z =	1.52 (P = 0.13)							0.01 0.1 i 10 100 Favours [conventional] Favours [intensive]

Leave out Han et al 2021

	Intensive Mana	gement	Conventional Manage	ement		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Goyal et al 2017	7	10	67	130	6.7%	1.36 [0.88, 2.11]	2017	+
Anadani et al 2019	485	942	92	259	10.4%	1.45 [1.22, 1.73]	2019	-
Cernik D et al 2019	202	376	132	314	10.6%	1.28 [1.09, 1.50]	2019	-
Chang et al 2019	32	48	17	42	7.0%	1.65 [1.08, 2.50]	2019	
Eva A. Mistry et al 2019	96	179	90	267	9.9%	1.59 [1.28, 1.98]	2019	-
Anadani et al 2020	283	540	222	479	11.0%	1.13 [1.00, 1.28]	2020	-
Han et al 2021	38	96	27	83	0.0%	1.22 [0.82, 1.81]	2021	
Mazighi et al 2021	67	152	69	153	9.4%	0.98 [0.76, 1.26]	2021	+
Yang et al 2022	192	404	247	406	10.9%	0.78 [0.69, 0.89]	2022	-
P. Upadhyaya et al 2023	28	44	27	59	7.8%	1.39 [0.97, 1.99]	2023	
Mistry et al 2023	17	37	36	76	6.9%	0.97 [0.64, 1.48]	2023	_ _
Nam et al 2023	61	155	80	147	9.5%	0.72 [0.57, 0.92]	2023	-
Total (95% CI)		2887		2332	100.0%	1.15 [0.97, 1.37]		•
Total events	1470		1079					
Heterogeneity: $Tau^2 = 0.0$	$7; Chi^2 = 70.20, d$	lf = 10 (P	< 0.00001); $I^2 = 86\%$					
Test for overall effect: Z =			,,					0.01 0.1 1 10 100 Favours [conventional] Favours [intensive]
								ravours (conventional) ravours (intensive)

Leave out Mazighi et al

•	Intensive Manag	gement	Conventional Manag	ement		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Goyal et al 2017	7	10	67	130	6.9%	1.36 [0.88, 2.11]	2017	
Anadani et al 2019	485	942	92	259	10.6%	1.45 [1.22, 1.73]	2019	+
Cernik D et al 2019	202	376	132	314	10.8%	1.28 [1.09, 1.50]	2019	+
Chang et al 2019	32	48	17	42	7.2%	1.65 [1.08, 2.50]	2019	
Eva A. Mistry et al 2019	96	179	90	267	10.1%	1.59 [1.28, 1.98]	2019	-
Anadani et al 2020	283	540	222	479	11.2%	1.13 [1.00, 1.28]	2020	•
Han et al 2021	38	96	27	83	7.5%	1.22 [0.82, 1.81]	2021	
Mazighi et al 2021	67	152	69	153	0.0%	0.98 [0.76, 1.26]	2021	
Yang et al 2022	192	404	247	406	11.1%	0.78 [0.69, 0.89]	2022	-
P. Upadhyaya et al 2023	28	44	27	59	8.0%	1.39 [0.97, 1.99]	2023	
Mistry et al 2023	17	37	36	76	7.1%	0.97 [0.64, 1.48]	2023	_
Nam et al 2023	61	155	80	147	9.7%	0.72 [0.57, 0.92]	2023	-
Total (95% CI)		2831		2262	100.0%	1.18 [0.99, 1.41]		•
Total events	1441		1037					
Heterogeneity: $Tau^2 = 0.0$	7; Chi ² = 69.57, d	f = 10 (P)	< 0.00001 ; $I^2 = 86\%$					
Test for overall effect: Z =								0.01 0.1 1 10 100 Favours [conventional] Favours [intensive]

Leave out Yang et al 2022*

Intensive Mana	gement	Conventional Manag	ement		Risk Ratio		Risk Ratio
Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M–H, Random, 95% CI
7	10	67	130	6.0%	1.36 [0.88, 2.11]	2017	
485	942	92	259	11.7%	1.45 [1.22, 1.73]	2019	+
202	376	132	314	12.1%	1.28 [1.09, 1.50]	2019	-
32	48	17	42	6.3%	1.65 [1.08, 2.50]	2019	
96	179	90	267	10.7%	1.59 [1.28, 1.98]	2019	-
283	540	222	479	12.9%	1.13 [1.00, 1.28]	2020	-
38	96	27	83	6.7%	1.22 [0.82, 1.81]	2021	+
67	152	69	153	9.9%	0.98 [0.76, 1.26]	2021	+
192	404	247	406	0.0%	0.78 [0.69, 0.89]	2022	
28	44	27	59	7.5%	1.39 [0.97, 1.99]	2023	
17	37	36	76	6.3%			
61	155	80	147	10.0%	0.72 [0.57, 0.92]	2023	-
	2579	i	2009	100.0%	1.21 [1.05, 1.39]		◆
1316		859					·
$J4: Chi^2 = 35.55, c$	df = 10 (P	$I = 0.0001$; $I^2 = 72\%$				ł	
= 2.64 (P = 0.008)							0.01 0.1 1 10 100 Favours [conventional] Favours [intensive]
	Events 7 485 202 32 96 283 38 67 192 28 17 61 1316 04; Chi ² = 35.55, d	7 10 485 942 202 376 32 48 96 179 283 540 38 96 67 152 192 404 28 44 17 37 61 155 2579 1316 04; Chi ² = 35.55, df = 10 (P	Events Total Events 7 10 67 485 942 92 202 376 132 32 48 17 96 179 90 283 540 222 38 96 27 67 152 69 192 404 247 28 44 27 17 37 36 61 155 80 Estable 1316 859 04; Chi ² = 35.55, df = 10 (P = 0.0001); l ² = 72%	EventsTotalEventsTotal710671304859429225920237613231432481742961799026728354022247938962783671526915319240424740628442759173736766115580147Z5792009131685904; Chi² = 35.55, df = 10 (P = 0.0001); l² = 72%	Events Total Events Total Weight 7 10 67 130 6.0% 485 942 92 259 11.7% 202 376 132 314 12.1% 32 48 17 42 6.3% 96 179 90 267 10.7% 283 540 222 479 12.9% 38 96 27 83 6.7% 67 152 69 153 9.9% 192 404 247 406 0.0% 28 44 27 59 7.5% 17 37 36 76 6.3% 61 155 80 147 10.0% Liste 859 04; Chi ² 35.55, df = 10 (P = 0.0001); l ² 72%	EventsTotalEventsTotalWeightM-H, Random, 95% CI710671306.0%1.36 [0.88, 2.11]4859429225911.7%1.45 [1.22, 1.73]20237613231412.1%1.28 [1.09, 1.50]324817426.3%1.65 [1.08, 2.50]961799026710.7%1.59 [1.28, 1.98]28354022247912.9%1.13 [1.00, 1.28]389627836.7%1.22 [0.82, 1.81]67152691539.9%0.98 [0.76, 1.26]1924042474060.0%0.78 [0.69, 0.89]284427597.5%1.39 [0.77, 1.99]173736766.3%0.97 [0.64, 1.48]611558014710.0%0.72 [0.57, 0.92]Last 125792009100.0%1.21 [1.05, 1.39]131685904; Chi ² = 35.55, df = 10 (P = 0.0001); l ² = 72%11	EventsTotalEventsTotalWeightM-H, Random, 95% CIYear710671306.0%1.36[0.88, 2.11]20174859429225911.7%1.45[1.22, 1.73]201920237613231412.1%1.28[1.09, 1.50]2019324817426.3%1.65[1.08, 2.50]2019961799026710.7%1.59[1.28, 1.98]201928354022247912.9%1.13[1.00, 1.28]2020389627836.7%1.22[0.82, 1.81]20211924042474060.0%0.78[0.69, 0.89]2022284427597.5%1.39[0.97, 1.99]2023173736766.3%0.97[0.64, 1.48]2023611558014710.0%0.72[0.57, 0.92]2023611558014710.0%0.72[0.57, 1.39]2023611558014710.0%0.72[0.57, 0.92]2023611558014710.0%0.72[0.57, 0.92]2023611556110(P = 0.0001); 1² = 72%12.1[1.05, 1.39]

Leave out Nam et al 2023*

	Intensive Manag	gement	Conventional Manage	ement		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M–H, Random, 95% Cl
Goyal et al 2017	7	10	67	130	6.6%	1.36 [0.88, 2.11]	2017	
Anadani et al 2019	485	942	92	259	10.8%	1.45 [1.22, 1.73]	2019	-
Cernik D et al 2019	202	376	132	314	11.1%	1.28 [1.09, 1.50]	2019	-
Chang et al 2019	32	48	17	42	6.9%	1.65 [1.08, 2.50]	2019	_ _ _
Eva A. Mistry et al 2019	96	179	90	267	10.2%	1.59 [1.28, 1.98]	2019	-
Anadani et al 2020	283	540	222	479	11.5%	1.13 [1.00, 1.28]	2020	-
Han et al 2021	38	96	27	83	7.2%	1.22 [0.82, 1.81]	2021	+-
Mazighi et al 2021	67	152	69	153	9.6%	0.98 [0.76, 1.26]	2021	+
Yang et al 2022	192	404	247	406	11.5%	0.78 [0.69, 0.89]	2022	+
P. Upadhyaya et al 2023	28	44	27	59	7.8%	1.39 [0.97, 1.99]	2023	
Mistry et al 2023	17	37	36	76	6.8%	0.97 [0.64, 1.48]	2023	
Nam et al 2023	61	155	80	147	0.0%	0.72 [0.57, 0.92]	2023	
Total (95% CI)		2828		2268	100.0%	1.21 [1.03, 1.43]		◆
Total events	1447		1026					
Heterogeneity: $Tau^2 = 0.0$	06; Chi ² = 58.52, d	f = 10 (P	< 0.00001 ; $I^2 = 83\%$				Ļ	
Test for overall effect: Z =	2.27 (P = 0.02)						(0.01 0.1 1 10 100 Favours [conventional] Favours [intensive]
								ravours (conventional) ravours (intensive)

Leave out Upadhyaya et al 2023

	Intensive Mana	gement	Conventional Manage	ement		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Goyal et al 2017	7	10	67	130	6.7%	1.36 [0.88, 2.11]	2017	
Anadani et al 2019	485	942	92	259	10.5%	1.45 [1.22, 1.73]	2019	+
Cernik D et al 2019	202	376	132	314	10.7%	1.28 [1.09, 1.50]	2019	+
Chang et al 2019	32	48	17	42	7.0%	1.65 [1.08, 2.50]	2019	
Eva A. Mistry et al 2019	96	179	90	267	9.9%	1.59 [1.28, 1.98]	2019	-
Anadani et al 2020	283	540	222	479	11.1%	1.13 [1.00, 1.28]	2020	+
Han et al 2021	38	96	27	83	7.3%	1.22 [0.82, 1.81]	2021	
Mazighi et al 2021	67	152	69	153	9.4%	0.98 [0.76, 1.26]	2021	+
Yang et al 2022	192	404	247	406	11.0%	0.78 [0.69, 0.89]	2022	+
P. Upadhyaya et al 2023	28	44	27	59	0.0%	1.39 [0.97, 1.99]	2023	
Mistry et al 2023	17	37	36	76	6.9%	0.97 [0.64, 1.48]	2023	_ _ _
Nam et al 2023	61	155	80	147	9.5%	0.72 [0.57, 0.92]	2023	-
Total (95% CI)		2939		2356	100.0%	1.14 [0.96, 1.36]		•
Total events	1480		1079					
Heterogeneity: $Tau^2 = 0.0$	$7; Chi^2 = 68.81, d$	f = 10 (P)	< 0.00001 ; $I^2 = 85\%$					
Test for overall effect: Z =			,,					0.01 0.1 1 10 100 Favours [conventional] Favours [intensive]

Leave out Mistry et al 2023

	Intensive Manag	gement	Conventional Manage	ment		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M–H, Random, 95% Cl
Goyal et al 2017	7	10	67	130	6.7%	1.36 [0.88, 2.11]	2017	
Anadani et al 2019	485	942	92	259	10.4%	1.45 [1.22, 1.73]	2019	+
Cernik D et al 2019	202	376	132	314	10.6%	1.28 [1.09, 1.50]	2019	-
Chang et al 2019	32	48	17	42	6.9%	1.65 [1.08, 2.50]	2019	
Eva A. Mistry et al 2019	96	179	90	267	9.8%	1.59 [1.28, 1.98]	2019	-
Anadani et al 2020	283	540	222	479	10.9%	1.13 [1.00, 1.28]	2020	•
Han et al 2021	38	96	27	83	7.2%	1.22 [0.82, 1.81]	2021	
Mazighi et al 2021	67	152	69	153	9.3%	0.98 [0.76, 1.26]	2021	+
Yang et al 2022	192	404	247	406	10.9%	0.78 [0.69, 0.89]	2022	+
P. Upadhyaya et al 2023	28	44	27	59	7.8%	1.39 [0.97, 1.99]	2023	
Mistry et al 2023	17	37	36	76	0.0%	0.97 [0.64, 1.48]	2023	
Nam et al 2023	61	155	80	147	9.4%	0.72 [0.57, 0.92]	2023	+
Total (95% CI)		2946		2339	100.0%	1.17 [0.99, 1.39]		•
Total events	1491		1070					
Heterogeneity: $Tau^2 = 0.0$	7; $Chi^2 = 70.12$, d	f = 10 (P)	< 0.00001 ; $I^2 = 86\%$					
Test for overall effect: Z =	1.80 (P = 0.07)							0.01 0.1 1 10 100 Favours [conventional] Favours [intensive]

Leave out one study analysis for primary outcome of observational studies Leave out Goyal et al 2017

	Intensive C	ontrol	Conventional C	ontrol		Risk Ratio		Risk	k Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Rand	dom, 95% CI	
Goyal et al 2017	7	10	67	130	0.0%	1.36 [0.88, 2.11]	2017			
Eva A. Mistry et al 2019	96	179	90	267	15.4%	1.59 [1.28, 1.98]	2019		-	
Anadani et al 2019	485	942	92	259	19.0%	1.45 [1.22, 1.73]	2019		-	
Cernik D et al 2019	202	376	132	314	20.5%	1.28 [1.09, 1.50]	2019		+	
Chang et al 2019	32	48	17	42	6.1%	1.65 [1.08, 2.50]	2019			
Anadani et al 2020	283	540	222	479	24.3%	1.13 [1.00, 1.28]	2020		-	
Han et al 2021	38	96	27	83	6.7%	1.22 [0.82, 1.81]	2021		+-	
P. Upadhyaya et al 2023	28	44	27	59	7.9%	1.39 [0.97, 1.99]	2023		 - -	
Total (95% CI)		2225		1503	100.0%	1.34 [1.19, 1.50]			•	
Total events	1164		607							
Heterogeneity: $Tau^2 = 0.02$	1; $Chi^2 = 11.7$	13, df =	6 (P = 0.08); I^2 =	46%					1 10	10
Test for overall effect: Z =	5.01 (P < 0.0))0001)						0.01 0.1 Favours Conventional	1 10 Favours Intensive	10

Leave out Anadani et al 2019

	Intensive C	ontrol	Conventional C	Control		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl
Goyal et al 2017	7	10	67	130	6.1%	1.36 [0.88, 2.11]	2017	
Eva A. Mistry et al 2019	96	179	90	267	17.6%	1.59 [1.28, 1.98]	2019	
Anadani et al 2019	485	942	92	259	0.0%	1.45 [1.22, 1.73]	2019	
Cernik D et al 2019	202	376	132	314	24.2%	1.28 [1.09, 1.50]	2019	• · · · · · · · · · · · · · · · · · · ·
Chang et al 2019	32	48	17	42	6.7%	1.65 [1.08, 2.50]	2019	
Anadani et al 2020	283	540	222	479	29.4%	1.13 [1.00, 1.28]	2020	-
Han et al 2021	38	96	27	83	7.3%	1.22 [0.82, 1.81]	2021	+
P. Upadhyaya et al 2023	28	44	27	59	8.7%	1.39 [0.97, 1.99]	2023	⊢
Total (95% CI)		1293		1374	100.0%	1.31 [1.17, 1.48]		•
Total events	686		582					
Heterogeneity: $Tau^2 = 0.0$	1; $Chi^2 = 9.33$	3, df = 6	$(P = 0.16); I^2 = 1$	36%			Ļ	
Test for overall effect: Z =	4.56 (P < 0.0	0001)					(0.01 0.1 1 10 100 Favours Conventional Favours Intensive

Leave out Cernik et al 2019

	Intensive C	ontrol	Conventional C	Control		Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI	
Goyal et al 2017	7	10	67	130	7.2%	1.36 [0.88, 2.11]	2017		
Eva A. Mistry et al 2019	96	179	90	267	18.1%	1.59 [1.28, 1.98]	2019		
Anadani et al 2019	485	942	92	259	21.7%	1.45 [1.22, 1.73]	2019	+	
Cernik D et al 2019	202	376	132	314	0.0%	1.28 [1.09, 1.50]	2019		
Chang et al 2019	32	48	17	42	7.8%	1.65 [1.08, 2.50]	2019	- - -	
Anadani et al 2020	283	540	222	479	26.7%	1.13 [1.00, 1.28]	2020	-	
Han et al 2021	38	96	27	83	8.5%	1.22 [0.82, 1.81]	2021	+	
P. Upadhyaya et al 2023	28	44	27	59	9.9%	1.39 [0.97, 1.99]	2023	+-	
Total (95% CI)		1859		1319	100.0%	1.36 [1.19, 1.55]		•	
Total events	969		542						
Heterogeneity: $Tau^2 = 0.0$	1; $Chi^2 = 11.1$	11, df =	6 (P = 0.08); I^2 =	= 46%			F		1
Test for overall effect: Z =	4.56 (P < 0.0)0001)	•				L	0.01 0.1 1 10 1 Favours Conventional Favours Intensive	00

Leave out Chang et al 2019

	Intensive C	ontrol	Conventional C	Control		Risk Ratio		Risk R	atio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Rando	m, 95% Cl	
Goyal et al 2017	7	10	67	130	5.2%	1.36 [0.88, 2.11]	2017			
Eva A. Mistry et al 2019	96	179	90	267	15.2%	1.59 [1.28, 1.98]	2019			
Anadani et al 2019	485	942	92	259	19.3%	1.45 [1.22, 1.73]	2019		+	
Cernik D et al 2019	202	376	132	314	21.1%	1.28 [1.09, 1.50]	2019		•	
Chang et al 2019	32	48	17	42	0.0%	1.65 [1.08, 2.50]	2019			
Anadani et al 2020	283	540	222	479	25.7%	1.13 [1.00, 1.28]	2020		r i i i i i i i i i i i i i i i i i i i	
Han et al 2021	38	96	27	83	6.2%	1.22 [0.82, 1.81]	2021	+	-	
P. Upadhyaya et al 2023	28	44	27	59	7.4%	1.39 [0.97, 1.99]	2023	ł	-	
Total (95% CI)		2187		1591	100.0%	1.32 [1.19, 1.47]			•	
Total events	1139		657							
Heterogeneity: $Tau^2 = 0.0$	1; $Chi^2 = 9.90$	0, df = 6	$(P = 0.13); I^2 = 3$	39%			F	.01 0.1 1	10	100
Test for overall effect: $Z =$	5.08 (P < 0.0)0001)					0.		Favours Intensive	100

Leave out Mistry et al 2019

		-							
-	Intensive Co	ontrol	Conventional C	ontrol		Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% CI	
Goyal et al 2017	7	10	67	130	4.4%	1.36 [0.88, 2.11]	2017	+-	
Eva A. Mistry et al 2019	96	179	90	267	0.0%	1.59 [1.28, 1.98]	2019		
Anadani et al 2019	485	942	92	259	21.4%	1.45 [1.22, 1.73]	2019	+	
Cernik D et al 2019	202	376	132	314	24.3%	1.28 [1.09, 1.50]	2019	-	
Chang et al 2019	32	48	17	42	4.9%	1.65 [1.08, 2.50]	2019		
Anadani et al 2020	283	540	222	479	33.1%	1.13 [1.00, 1.28]	2020	-	
Han et al 2021	38	96	27	83	5.4%	1.22 [0.82, 1.81]	2021	+	
P. Upadhyaya et al 2023	28	44	27	59	6.5%	1.39 [0.97, 1.99]	2023	<u>├</u>	
Total (95% CI)		2056	,	1366	100.0%	1.28 [1.17, 1.41]		•	
Total events	1075		584						
Heterogeneity: $Tau^2 = 0.00$	$C_{1}; Chi^{2} = 7.38$	3, df = 6	$P = 0.29$; $I^2 = 1$	19%			F		0 10
Test for overall effect: $Z = S$	5.14 (P < 0.0	0001)	. ,,				0.0	01 0.1 1 1 Favours Conventional Favours Inter	0 10 nsive

Leave out Anadani et 2020

Intensive C	ontrol	Conventional Co	ntrol		Risk Ratio		Risk Ratio
Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
7	10	67	130	4.4%	1.36 [0.88, 2.11]	2017	
96	179	90	267	18.1%	1.59 [1.28, 1.98]	2019	+
485	942	92	259	27.6%	1.45 [1.22, 1.73]	2019	-
202	376	132	314	33.0%	1.28 [1.09, 1.50]	2019	=
32	48	17	42	4.9%	1.65 [1.08, 2.50]	2019	_
283	540	222	479	0.0%	1.13 [1.00, 1.28]	2020	
38	96	27	83	5.4%	1.22 [0.82, 1.81]	2021	
28	44	27	59	6.7%	1.39 [0.97, 1.99]	2023	-
	1695		1154	100.0%	1.40 [1.28, 1.54]		•
888		452					
0; $Chi^2 = 3.82$, df = 6	$(P = 0.70); I^2 = 0\%$	6			1	0.01 0.1 1 10 100
7.19 (P < 0.0	0001)						0.01 0.1 1 10 100 Favours Conventional Favours Intensive
	Events 7 96 485 202 32 283 38 28 90; Chi² = 3.82	7 10 96 179 485 942 202 376 32 48 283 540 38 96 28 44 1695 888	Events Total Events 7 10 67 96 179 90 485 942 92 202 376 132 32 48 17 283 540 222 38 96 27 28 44 27 I695 888 452 10; Chi ² = 3.82, df = 6 (P = 0.70); l ² = 0%	EventsTotalEventsTotal710671309617990267485942922592023761323143248174228354022247938962783284427591695115488845290; Chi ² = 3.82, df = 6 (P = 0.70); l ² = 0%	$\begin{tabular}{ c c c c c c } \hline Events & Total & Events & Total & Weight \\ \hline 7 & 10 & 67 & 130 & 4.4\% \\ \hline 96 & 179 & 90 & 267 & 18.1\% \\ \hline 485 & 942 & 92 & 259 & 27.6\% \\ \hline 202 & 376 & 132 & 314 & 33.0\% \\ \hline 32 & 48 & 17 & 42 & 4.9\% \\ \hline 283 & 540 & 222 & 479 & 0.0\% \\ \hline 38 & 96 & 27 & 83 & 5.4\% \\ \hline 28 & 44 & 27 & 59 & 6.7\% \\ \hline 1695 & 1154 & 100.0\% \\ \hline 888 & 452 \\ 10; \ Chi^2 = 3.82, \ df = 6 \ (P = 0.70); \ l^2 = 0\% \\ \hline \end{tabular}$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	EventsTotalEventsTotalWeightM-H, Random, 95% CIYear710671304.4%1.36[0.88, 2.11]2017961799026718.1%1.59[1.28, 1.98]20194859429225927.6%1.45[1.02, 1.73]201920237613231433.0%1.28[1.09, 1.50]2019324817424.9%1.65[1.08, 2.50]20192835402224790.0%1.13[1.00, 1.28]2020389627835.4%1.22[0.82, 1.81]2021284427596.7%1.39[0.97, 1.99]2023Inst4100.0%1.40[1.28, 1.54]88845210%1.40[1.28, 1.54]10%

Leave out Han et al 2021

	Intensive C	ontrol	Conventional C	ontrol				Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl
Goyal et al 2017	7	10	67	130	5.7%	1.36 [0.88, 2.11]	2017	
Eva A. Mistry et al 2019	96	179	90	267	15.6%	1.59 [1.28, 1.98]	2019	+
Anadani et al 2019	485	942	92	259	19.2%	1.45 [1.22, 1.73]	2019	-
Cernik D et al 2019	202	376	132	314	20.7%	1.28 [1.09, 1.50]	2019	-
Chang et al 2019	32	48	17	42	6.2%	1.65 [1.08, 2.50]	2019	_ _ _
Anadani et al 2020	283	540	222	479	24.6%	1.13 [1.00, 1.28]	2020	-
Han et al 2021	38	96	27	83	0.0%	1.22 [0.82, 1.81]	2021	
P. Upadhyaya et al 2023	28	44	27	59	8.0%	1.39 [0.97, 1.99]	2023	
Total (95% CI)		2139		1550	100.0%	1.35 [1.20, 1.51]		•
Total events	1133		647					
Heterogeneity: $Tau^2 = 0.0$	1; $Chi^2 = 11.0$	06, df =	6 (P = 0.09); $I^2 =$	46%				0.01 0.1 1 10 100
Test for overall effect: $Z =$	5.12 (P < 0.0	0001)						0.01 0.1 1 10 100 Favours Conventional Favours Intensive

Leave out Upadhyaya et al 2023

1	Intensive C	ontrol	Conventional C	ontrol		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Rano	dom, 95% CI	
Goyal et al 2017	7	10	67	130	5.8%	1.36 [0.88, 2.11]	2017		+	
Eva A. Mistry et al 2019	96	179	90	267	15.8%	1.59 [1.28, 1.98]	2019			
Anadani et al 2019	485	942	92	259	19.4%	1.45 [1.22, 1.73]	2019		-	
Cernik D et al 2019	202	376	132	314	21.0%	1.28 [1.09, 1.50]	2019		+	
Chang et al 2019	32	48	17	42	6.3%	1.65 [1.08, 2.50]	2019			
Anadani et al 2020	283	540	222	479	24.9%	1.13 [1.00, 1.28]	2020		-	
Han et al 2021	38	96	27	83	6.9%	1.22 [0.82, 1.81]	2021		+	
P. Upadhyaya et al 2023	28	44	27	59	0.0%	1.39 [0.97, 1.99]	2023			
Total (95% CI)		2191		1574	100.0%	1.34 [1.19, 1.50]			•	
Total events	1143		647							
Heterogeneity: $Tau^2 = 0.0$	01; $Chi^2 = 11.0$)3, df =	6 (P = 0.09); $I^2 =$	46%			- E		1 10 1	
Test for overall effect: Z =	4.92 (P < 0.0	0001)						0.01 0.1 Favours Conventional		100

Leave out one study analysis for RCTs Leave out Yang et al 2022*

	Intensive Co	Control	Conventional C	Control				Risk Ratio
Study or Subgroup	Events	Total	l Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Mazighi et al 2021	67	152	69	153	39.7%	0.98 [0.76, 1.26]	2021	+
Yang et al 2022	192	404	247	406	0.0%	0.78 [0.69, 0.89]	2022	
Nam et al 2023	61	155	80	147	40.6%	0.72 [0.57, 0.92]	2023	
Mistry et al 2023	17	37	36	76	19.8%	0.97 [0.64, 1.48]	2023	-
Total (95% CI)		344	<i>j</i> .	376	100.0%	0.86 [0.70, 1.07]		•
Total events	145		185					
Heterogeneity: Tau ² =	= 0.01; Chi ² =	- 3.23, dʻ	f = 2 (P = 0.20);	$I^2 = 38\%$				0.01 0.1 1 10 100
Test for overall effect:	. Z = 1.34 (P =	= 0.18)						Favours Conventional Favours Intensive

Leave out Nam et al 2023*

	Intensive C	ontrol	Conventional C	Control		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Events Total		M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Mazighi et al 2021	67	152	69	153	29.2%	0.98 [0.76, 1.26]	2021	-
Yang et al 2022	192	404	247	406	57.8%	0.78 [0.69, 0.89]	2022	
Nam et al 2023	61	155	80	147	0.0%	0.72 [0.57, 0.92]	2023	
Mistry et al 2023	17	37	36	76	13.0%	0.97 [0.64, 1.48]	2023	+
Total (95% CI)		593		635	100.0%	0.86 [0.73, 1.01]		◆
Total events	276		352					
Heterogeneity: Tau ² =	= 0.01; Chi ² =	3.03, df	$r^2 = 2 (P = 0.22);$	$I^2 = 34\%$				
Test for overall effect:	Z = 1.83 (P =	= 0.07)						0.01 0.1 1 10 10 Favours Conventional Favours Intensive

Leave out Mistry et al 2023

	Intensive C	ontrol	Conventional C	Control		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	l Events Tot		Weight	M-H, Random, 95% CI	Year	M–H, Random, 95% Cl
Mazighi et al 2021	67	152	69	153	24.3%	0.98 [0.76, 1.26]	2021	-
Yang et al 2022	192	404	247	406	50.6%	0.78 [0.69, 0.89]	2022	
Nam et al 2023	61	155	80	147	25.0%	0.72 [0.57, 0.92]	2023	
Mistry et al 2023	17	37	36	76	0.0%	0.97 [0.64, 1.48]	2023	
Total (95% CI)		711		706	100.0%	0.81 [0.70, 0.94]		•
Total events	320		396					
Heterogeneity: Tau ² =	= 0.01; Chi ² =	3.25, df	r = 2 (P = 0.20);	$I^2 = 38\%$				
Test for overall effect	Z = 2.83 (P =	= 0.005)						6.01 0.1 1 10 100 Favours Conventional Favours Intensive

Leave out Mazighi et al 2021

	Intensive C	ontrol	Conventional C	ontrol		Risk Ratio		Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Rai	ndom, 95% CI		
Mazighi et al 2021	67	152	69	153	0.0%	0.98 [0.76, 1.26]	2021				
Yang et al 2022	192	404	247	406	73.0%	0.78 [0.69, 0.89]	2022				
Nam et al 2023	61	155	80	147	20.2%	0.72 [0.57, 0.92]	2023	-	-		
Mistry et al 2023	17	37	36	76	6.8%	0.97 [0.64, 1.48]	2023		+		
Total (95% CI)		596		629	100.0%	0.78 [0.70, 0.87]			•		
Total events	270		363								
Heterogeneity: Tau ² =	= 0.00; Chi ² =	1.39, di	f = 2 (P = 0.50); I	$l^2 = 0\%$					-	10 1	
Test for overall effect	: Z = 4.41 (P	< 0.000	1)					0.01 0.1 Favours Convention			100

Intensive SBP Control compared to Conventional SBP Control for Patients with Acute Ischemic Stroke undergoing thrombectomy

Patient or population: Patients with Acute Ischemic Stroke undergoing thrombectomy Setting: Acute ischemic Stroke undergoing thrombectomy Intervention: Intensive SBP Control Comparison: Conventional SBP Control

	Anticipated absolu	ute effects* (95% CI)				
Outcomes	Risk with Conventional SBP Control	Risk with Intensive SBP Control	Relative effect (95% Cl)	№ of participants (studies)	Certainty of the evidence (GRADE)	Comments
mRS 0-2 at 90 days	413 per 1,000	549 per 1,000 (499 to 594)	RR 1.33 (1.21 to 1.44)	3868 (8 non-randomised studies)	⊕⊕⊕⊖ Moderate ^{a,b}	Intensive SBP Control probably results in an increased chances of mRS 0-2 at 90 days.
Death at 90 days	230 per 1,000	165 per 1,000 (133 to 202)	RR 0.72 (0.58 to 0.88)	3868 (8 non-randomised studies)	⊕⊕⊕⊖ Moderate ^{a,b}	Intensive SBP Control likely reduces death at 90 days.
Symptomatic ICH	75 per 1,000	47 per 1,000 (32 to 68)	RR 0.62 (0.42 to 0.90)	2642 (5 non-randomised studies)	⊕⊕⊖⊖ Low ^{a,b,c}	Intensive SBP Control may reduce symptomatic ICH.
Decompressive hemicraniectomy	68 per 1,000	26 per 1,000 (17 to 40)	RR 0.39 (0.25 to 0.59)	2323 (3 non-randomised studies)	⊕⊕⊖⊖ Low ^{a,b,d}	Intensive SBP Control may reduce decompressive hemicraniectomy.
mRS 0-2 at 90 days (RCTs)	552 per 1,000	459 per 1,000 (387 to 530)	RR 0.83 (0.70 to 0.96)	1530 (4 RCTs)	⊕⊕⊕⊖ Moderate ^e	Conventional SBP control results in improved chances of mRS 0-2 at 90 days
Death at 90 days	140 per 1,000	159 per 1,000 (125 to 202)	RR 1.13 (0.89 to 1.44)	1534 (4 RCTs)	⊕⊕⊕⊖ Moderate ^e	No effect on mortality at 90 days between both arms.
Symptomatic ICH	65 per 1,000	73 per 1,000 (51 to 105)	RR 1.13 (0.78 to 1.62)	1540 (4 RCTs)	⊕⊕⊕⊖ Moderate ^e	Neither Intensive nor conventional SBP Control result in any difference in symptomatic ICH rates.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; RR: risk ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

a. Inconsistencies in BP recordings and usage of Mean SBP for defining the intensive arm. Measurement and Observational Bias possible.

b. Cut offs used across different studies different

- c. Low event rates in Two Studies-Goyal et al only 1/10 patients in the intensive arm and in P.Upadhyaya et al only 1/44 patients had symptomatic ICH
- d. Low event rates and similar rates in P.Upadhyaya et al-1/44 in intensive arm and 1/59 in conventional arm

e. Deviations from intended BP Control arm-Domain 2

GRADE EVIDENCE PROFILE

Author(s): Baikuntha Panigrahi, Rohit Bhatia, Partha Haldar

Question: Intensive SBP Control compared to Conventional SBP Control for Patients with Acute Ischemic Stroke undergoing thrombectomy

Setting: Acute ischemic Stroke undergoing thrombectomy

Bibliography:

	Certainty assessment							patients	Effec	t		
Nº of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Intensive SBP Control	Conventional SBP Control	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance

mRS 0-2 at 90 days

8	non- randomised studies	serious ^{a,b}	not serious	not serious	not serious	none	1171/2235 (52.4%)	674/1633 (41.3%)	RR 1.33 (1.21 to 1.44)	136 more per 1,000 (from 87 more to 182 more)		
---	-------------------------------	------------------------	-------------	-------------	-------------	------	-------------------	------------------	----------------------------------	---	--	--

Death at 90 days

8	non- randomised studies	serious ^{a,b}	not serious	not serious	not serious	none	373/2235 (16.7%)	375/1633 (23.0%)	RR 0.72 (0.58 to 0.88)	64 fewer per 1,000 (from 96 fewer to 28 fewer)	Moderate	
---	-------------------------------	------------------------	-------------	-------------	-------------	------	------------------	------------------	-------------------------------	--	----------	--

Symptomatic ICH

Decompressive hemicraniectomy

3 non- s randomised studies	serious ^{a,b} not serious	not serious serious ^d	none	43/1526 (2.8%)	54/797 (6.8%)	RR 0.39 (0.25 to 0.59)	41 fewer per 1,000 (from 51 fewer to 28 fewer)		
-----------------------------------	------------------------------------	----------------------------------	------	----------------	---------------	----------------------------------	--	--	--

mRS 0-2 at 90 days (RCTs)

fewer)

Death at 90 days

Certainty assessment							№ of patients		Effect			1
Nº of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Intensive SBP Control	Conventional SBP Control	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
4	randomised trials	serious ^e	not serious	not serious	not serious	none	114/750 (15.2%)	110/784 (14.0%)	RR 1.13 (0.89 to 1.44)	18 more per 1,000 (from 15 fewer to 62 more)	⊕⊕⊕⊖ Moderate	
Symptomati	ic ICH											
4	randomised trials	serious	not serious	not serious	not serious	none	56/753 (7.4%)	51/787 (6.5%)	RR 1.13 (0.78 to 1.62)	8 more per 1,000 (from 14 fewer to 40 more)	⊕⊕⊕⊖ Moderate	

CI: confidence interval; RR: risk ratio

Explanations

a. Inconsistencies in BP recordings and usage of Mean SBP for defining the intensive arm. Measurement and Observational Bias possible.
b. Cut offs used across different studies different
c. Low event rates in Two Studies-Goyal et al only 1/10 patients in the intensive arm and in P.Upadhyaya et al only 1/44 patients had symptomatic ICH
d. Low event rates and similar rates in P.Upadhyaya et al-1/44 in intensive arm and 1/59 in conventional arm
e. Deviations from intended BP Control arm-Domain 2